stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) Total debt
CareDx, Inc.'s total debt at the end of fiscal 2022 was $39.0M, up 82.6% from $21.4M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $35.2M. Over the past ten years it has ranged from $421.0K (fiscal 2018) to $39.0M (fiscal 2022) — the current reading is the highest in ten years. CareDx, Inc. ranks 29th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $39.0M | 82.64% |
| FY2021 | $21.4M | 17.49% |
| FY2020 | $18.2M | 451.20% |
| FY2019 | $3.3M | 683.14% |
| FY2018 | $421.0K | (98.76%) |
| FY2017 | $34.1M | 42.24% |
| FY2016 | $23.9M | 52.00% |
| FY2015 | $15.8M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $35.2M | (3.26%) |
| Jun 2023 | $36.4M | (3.57%) |
| Mar 2023 | $37.7M | (3.21%) |
| Dec 2022 | $39.0M | (2.31%) |
| 27 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SHC Sotera Health Company compare | $2.2B |
| RDNT RadNet, Inc. compare | $1.3B |
| NEO NeoGenomics, Inc. compare | $378.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $334.9M |
| WGS GeneDx Holdings Corp. compare | $96.8M |
| BLLN BillionToOne, Inc. compare | $89.1M |
| CDNA CareDx, Inc. | $35.2M |
| VCYT Veracyte, Inc. compare | $14.0M |
| GRAL GRAIL, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement